Adaptive Biotechnologies Corporation (ADPT) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 11 Buy, 4 Hold, 2 Sell.
The consensus price target is $21.25 (low: $21.00, high: $22.00), representing an upside of 46.2% from the current price $14.53.
Analysts estimate Earnings Per Share (EPS) of $-1.12 and revenue of $0.18B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.08 vs est $-1.12 (beat +3.1%). 2025: actual $-0.39 vs est $-0.49 (beat +20.8%). Analyst accuracy: 85%.
ADPT Stock — 12-Month Price Forecast
$21.25
▲ +46.25% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Adaptive Biotechnologies Corporation, the average price target is $21.25, with a high forecast of $22.00, and a low forecast of $21.00.
The average price target represents a +46.25% change from the last price of $14.53.
Highest Price Target
$22.00
Average Price Target
$21.25
Lowest Price Target
$21.00
ADPT Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Adaptive Biotechnologies Corporation in the past 3 months
EPS Estimates — ADPT
85%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.08
vs Est –$1.12
▲ 3.2% off
2025
Actual –$0.39
vs Est –$0.49
▲ 26.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ADPT
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.179B
vs Est $0.178B
▲ 0.7% off
2025
Actual $0.277B
vs Est $0.266B
▲ 4.0% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
